Zuk Malgorzata, Migdal Anna, Jagiellowicz-Kowalska Dorota, Mazurkiewicz Katarzyna, Sadel-Wieczorek Anna, Brzezinska-Rajszys Grazyna
Department of Cardiology, The Children's Memorial Health Institute, Al. Dzieci Polskich 20, 04-730, Warsaw, Poland.
Pediatr Cardiol. 2017 Apr;38(4):754-761. doi: 10.1007/s00246-017-1575-z. Epub 2017 Feb 27.
Six-minute walk test (6MWT) is a submaximal exercise test applied for evaluation of adults with pulmonary arterial hypertension (PAH). It was widely used as an endpoint in the clinical trials. The aim of the study was to assess the usefulness of 6MWT in management of children with PAH and to establish correlations with other clinical features. 164 6MWT were performed in 15 children between 5 and 18 years with PAH confirmed by right heart catheterization (102 in patients with shunt, 62 without shunt). Distance in 6MWT (6MWD)-% of predicted for age and gender, desaturation at the maximum effort, peak heart rate (HR)-% of maximal HR, were compared to the level of NTproBNP, WHO-FC, echocardiography parameters, and events of PAH treatment intensification. 6MWD had low negative correlation with peak HR (τ -0.1 p = 0,03), negative correlation with NTproBNP (τ -0.17 p = 0.002), and no dependence on echocardiography parameters. The presence of shunt was associated with lower 6MWD, lower blood saturation at rest, and higher desaturation after effort. Patients in III/IV WHO-FC achieved higher rest HR and maximal HR in comparison to patients in I/II WHO-FC (63.1 vs. 55.2% p < 0.01) and lower 6MWD (64.3 vs. 77.5% p < 0.01). In 14 out of 20 6MWT performed after treatment intensification, increase of distance was observed. The results of 6MWT were consistent with clinical status (WHO-FC, NTproBNP) but not with echocardiography parameters. 6MWT may be the source of additional information in management of children with PAH.
六分钟步行试验(6MWT)是一种次极量运动试验,用于评估患有肺动脉高压(PAH)的成年人。它在临床试验中被广泛用作终点指标。本研究的目的是评估6MWT在PAH患儿管理中的作用,并建立其与其他临床特征的相关性。对15例年龄在5至18岁、经右心导管检查确诊为PAH的儿童进行了164次6MWT(分流患者102例,无分流患者62例)。将6MWT中的步行距离(6MWD)——根据年龄和性别预测的百分比、最大努力时的血氧饱和度下降、峰值心率(HR)——最大HR的百分比,与NTproBNP水平、世界卫生组织功能分级(WHO-FC)、超声心动图参数以及PAH治疗强化事件进行比较。6MWD与峰值HR呈低度负相关(τ -0.1,p = 0.03),与NTproBNP呈负相关(τ -0.17,p = 0.002),且与超声心动图参数无关。分流的存在与较低的6MWD、静息时较低的血氧饱和度以及运动后较高的血氧饱和度下降有关。与WHO-FC I/II级患者相比,WHO-FC III/IV级患者的静息HR和最大HR更高(63.1%对55.2%,p < 0.01),6MWD更低(64.3%对77.5%,p < 0.01)。在治疗强化后进行的20次6MWT中,有14次观察到步行距离增加。6MWT的结果与临床状态(WHO-FC、NTproBNP)一致,但与超声心动图参数不一致。6MWT可能是PAH患儿管理中额外信息的来源。